Keywords: Positive Aspects of Caregiving Experience; Family Burden; Caregivers; Opioid; Substance.

Disclosure of Interest: None Declared

## **EPP0914**

## Pragmatic Clinical Trial to Improve Screening and Treatment for Opioid Use Disorder in Primary Care

R. Rossom<sup>1,2</sup>

<sup>1</sup>HealthPartners Institute, Minneapolis and <sup>2</sup>University of Minnesota, Minneapolis

doi: 10.1192/j.eurpsy.2023.1194

**Introduction:** Opioid-related deaths continue to rise in the U.S. A clinical decision support (CDS) system to help primary care clinicians (PCCs) identify and treat patients with opioid use disorder (OUD) could help address this crisis.

**Objectives:** To implement and test an OUD-CDS system in three health systems for the diagnosis and treatment of OUD in 90 primary care clinics.

**Methods:** In this cluster-randomized trial, primary care clinics in three healthcare systems were randomized to receive or not receive access to an OUD-CDS system. The OUD-CDS system alerts PCCs and patients to elevated risk of OUD and supports OUD screening and treatment. It includes guidance on OUD screening and diagnosis, treatment selection, starting and maintaining patients on buprenorphine for waivered clinicians, and screening for common comorbid conditions. The primary study outcome is, of patients at high risk for OUD, the percentage receiving an OUD diagnosis within 30 days of index visit. Additional outcomes are, of patients at high risk for or with a diagnosis of OUD, (a) the percentage receiving a maloxone prescription, or (b) the percentage receiving a medication for OUD (MOUD) prescription or referral to specialty care within 30 days of an index visit, and (c) total days covered by a MOUD prescription within 90 days of an index visit.

**Results:** The intervention started in April 2021 and continues through December 2023, with successful implementatio and uptake. PCCs and patients in 90 clinics are included; study results are expected in 2024.

## Image:




Image 2:

Disgrose	Select OUD Medication	Subuxone.()(Waberred)	Other Care
Data COOL resolution standards for your prior to constant     Datase Annotacity     You O Too In your paleer ready for treatment			Patient Education Materials © DLO Medication. Dentities © Statement © Mathematic © Mathematic © Mathematic © Mathematic © State Line. of IN/Devos
Treatment Selection	-		
b) any of these clinical conditions apply to your patient? Severa Iver classe? Or yes * No	GO Suboxone: Prescr	Re (f Walvered)	Select and Continue
Severe respondory disease? O Yes 💌 No		11 Michael Colorest Pro-	
Active allochol use disorder? (Use the (2 TAPS to somer) O Vas 🔻 No	GO Suboxone: Refer	o Marvered Prenary Care	Refer and Continue
Beroodapeoine or 2-drug (Zopicem, Zopicone, Exopologine, Zeleptini use? 🔿 Ves 📽 No	GO Subcener: Befer 1	to Specialty Care	Refer and Continue
Chronic pain?			
ts the patient at risk for suicide? ○ Yes 🎕 No	GO M Halbroose Re	fer to Specially Care	Refer and Continue
	GO Methadaret Part	list of Community Clinics	Print and Continue

### Image 3:

Select OUD Medication	Subcaces (II Weivered)	Other Care						
see heliation	Subsecore Main	fenance						
Do you want to perform an in-clinic induction o #4-borne O In-clinic	r an al-home induction?							
Peace Orders Orders Sciences Sing of patient has a low tolerance for optical: (3) Print induction mitructions (Sing) Order Sciences Ang if patient has a nonemate to expecte (3) Print induction mitructions (Ang) Order Sciences Torg (patient has high tolerance for optical: (3) Print induction interactions (Ang) Order Sciences Mit								
					Order UP3     Consider Classifies for basisfies on unbeformed associates for nations unbest includes in			
					Consider Zoftan for breakthrough withd	avial symptoms		
Optional Print Clinical Opiate Withdraval Scale (C	0///5) for patients to use at home to assess withdrawal							
		CONTINUE TO OTHER CAR						
	Medication Dryse and typeform in in-direc inductor i # Abore O in-drive Drose Clarks O obs Shoome Sing Fysters has a h O obs Shoome Sing Fyste	Institution         Soldialized ()         Institution           Deprins used by polyters at in clinic inductions or an advance inductors?         Soldialized ()         Soldialized ()           Deprins used by polyters at in clinic inductors or an advance inductors?         Soldialized ()         Soldialized ()           Deprins used by polyters at in clinic inductors or an advance inductors?         Soldialized ()         Soldialized ()           Deprins used by polyters in a soldialized inductor inductors and the soldialized inductors and the soldialin adinductors and the soldialin adinductors and the soldi						

**Conclusions:** If effective, this OUD-CDS intervention could improve screening of at-risk patients and rates of OUD treatment for people with OUD, a significant step in decreasing the morbidity and mortality associated with OUD.

Disclosure of Interest: None Declared

## EPP0915

# Characterization of cannabis withdrawal symptoms and serum levels of neurotransmitters among cannabisdependent smokers during sustained abstinence within a controlled residential environment

R. Sharma<sup>1</sup>\*, S. K. Tikka<sup>2</sup>, A. R. Bhute<sup>1</sup>, P. Dhamija<sup>3</sup> and B. K. Bastia<sup>1</sup>

<sup>1</sup>Forensic Medicine and Toxicology, AIIMS, Rishikesh, Uttarakhand; <sup>2</sup>Psychiatry, AIIMS, Bibinagar, Telangana and <sup>3</sup>Pharmacology, AIIMS, Rishikesh, India

\*Corresponding author.


doi: 10.1192/j.eurpsy.2023.1195

**Introduction:** Cannabis (aka marijuana) is the most frequently consumed illicit substance worldwide, and a subset of frequent cannabis smokers (up to 30%) develop dependence. A less well-known consequence of cannabis dependence is withdrawal syn-

drome, characterized by a time-dependent constellation of symptoms (Lafaye et al. Dialogues Clin Neurosci 2017;19(3), 309-316). **Objectives:** This study aims to prospectively assess the course of cannabis withdrawal symptoms within a controlled inpatient detoxification setting and to correlate the severity of withdrawal symptoms with the serum levels of neurotransmitters (NT).

**Methods:** N=45 treatment-seeking chronic cannabis dependents (assessed by ICD-10) were enrolled, and their withdrawal symptoms were assessed prospectively from admission (Day-0) to 28 days using Marijuana withdrawal checklist (MWC). Sociodemographic characteristics and self-reported drug use histories were reported. Serum levels of dopamine, serotonin, norepinephrine, epinephrine, and cortisol were measured. Cannabis abstinence symptoms were assessed daily using MWC for 4 weeks, and serum neurotransmitter levels were analyzed at admission (Day 0), 7, 14, 21, and 28. Comparison between groups was done using Friedman's test. Correlation between NT level and MWC scores was performed using linear regression spearman correlation analysis

**Results:** The follow-up NT levels from Day 0 to 28 showed a significant (p<0.05) decrease in serotonin and dopamine, whereas epinephrine levels showed a significant increase (Fig 1) with the course of withdrawal. Withdrawal symptoms like decreased appetite, sweating, and craving were significantly and positively correlated with serotonin, dopamine, and epinephrine NT levels (Fig 2). **Image:** 



**Conclusions:** Findings support the presence of clinically significant cannabis withdrawal symptoms with NT levels in subjects with cannabis dependence seeking substance abuse treatment. The data of this study determine the relationship between observed withdrawal symptoms and changes in brain chemistry and evaluate its possible utility as a predictor of relapse.

## Disclosure of Interest: None Declared

#### **EPP0916**

# What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?

## R. Weiss\* and M. L. Griffin

Psychiatry/Division of Alcohol, Drugs, and Addiction, Harvard Medical School/McLean Hospital, Belmont, MA, United States \*Corresponding author. doi: 10.1192/j.eurpsy.2023.1196

**Introduction:** Studies consistently show that patients with prescription opioid use disorder (OUD) respond to buprenorphine treatment. Few studies have followed these patients in the longterm. Our longitudinal research has shown opioid abstinence to be associated most strongly with opioid agonist/partial agonist treatment. We also found that many patients used agonist treatment inconsistently; questions remain about the benefits of intermittent opioid agonist treatment.

**Objectives:** We examined patients during the 3.5 years following their entry into a 3-month trial of treatment for prescription OUD. The current analysis compared opioid use outcomes among patients who reported receipt of agonist treatment consistently, inconsistently, or never.

**Methods:** This secondary analysis (N=309) of a U.S. multi-site randomized controlled trial of treatment for prescription OUD assessed variability in receiving opioid agonist treatment during the 3.5-year follow-up period, and the association between agonist treatment and opioid abstinence. Assessments were collected at months 18, 30, and 42 following treatment entry; patients were asked if they were currently taking agonist treatment and whether they had used other opioids in the previous month. Patients with only one follow-up assessment (n=29) were excluded from this analysis.

**Results:** Most patients reported current opioid abstinence on at least one follow-up visit: 38% were always abstinent, 41% sometimes, and 21% never. Twenty-three percent always reported currently using agonist treatment, 26% sometimes, and 51% never. Patients consistently reporting agonist use were most likely to always be opioid-abstinent in the past month (69%), with 25% sometimes and 6% never abstinent. Patients who never reported agonist use were equally likely to be abstinent never (32%), sometimes (35%), and always (32%). Patients who sometimes reported receiving agonists were most likely to report abstinence sometimes (65%); 14% never reported abstinence, and 21% always did.

Those consistently receiving agonist treatment were more likely to always be opioid-abstinent (69%) than those sometimes (21%) or never (32%) receiving agonists. Those never receiving agonist treatment were more likely to never report opioid abstinence (32%) than were those sometimes (14%) or always (6%) receiving agonists. Interestingly, those who sometimes received agonists were more likely to be abstinent than those who never received agonists: those who sometimes received agonists were more likely to be abstinent sometimes than those who never received agonists (65% vs. 35%) and less likely to never be abstinent than were those who never received agonists (14% vs. 32%).

**Conclusions:** Receiving opioid agonist treatment has been shown to be associated with opioid abstinence during long-term follow-up.